Cost control rationale for pharmacare does not stand up to scrutiny: Canadian Health Policy Institute
TORONTO, March 14, 2024 (GLOBE NEWSWIRE) -- The latest edition of an annual study from the Canadian Health Policy Institute concludes that the cost control rationale for national pharmacare is not supported by the facts.
- TORONTO, March 14, 2024 (GLOBE NEWSWIRE) -- The latest edition of an annual study from the Canadian Health Policy Institute concludes that the cost control rationale for national pharmacare is not supported by the facts.
- It is a symbolic step toward a national pharmacare program that will replace existing public and private drug plans.
- Pharmacare advocates are betting a single payer can demand deeper discounts without jeopardizing the availability of new medicines in Canada.
- Excessive cost controls for patented medicines are counterproductive.”
“It appears unlikely that the current government will rethink its pharmacare policy.